The exacerbation of post myocardial infarction cardiac dysfunction with T-1095 in the experimental setting suggests the need for caution with the use of dual SGLT1/2 inhibitors in humans, reinforcing the prudent approach taken by regulatory authorities in specifically studying patients with cardiovascular disease before bringing a new glucose-lowering drug to market. This evidence concerns the gene SLC5A1 and myocardial infarction.